Clinical Trial Application in Canada: How the CTA Process Works Under Division 5 of the Food and Drug Regulations

Sponsors who’ve filed an IND with the FDA often assume the Canadian CTA is roughly the same process with a different cover page. That assumption tends to cost 30 to 60 days — sometimes more — when Health Canada issues a Notice of Non-Compliance and the clock resets entirely.

Canada’s clinical trial authorization framework is distinct. It’s governed by Division 5 of Part C of the Food and Drug Regulations (C.05.001 through C.05.013), administered by Health Canada’s Therapeutic Products Directorate (TPD) for small molecules and by the Biologics and Genetic Therapies Directorate (BGTD) for biologics, vaccines, and gene therapies. Understanding which directorate owns your file — and what each expects in the quality package — is the foundation everything else builds on.

The Regulatory Foundation: What Division 5 Actually Requires

Division 5 has governed Canadian clinical trial authorization for drugs since amendments to the Food and Drug Regulations came into force in September 2001. The framework applies to any clinical trial involving a “new drug” as defined under the Act — which, in practical terms, means any investigational medicinal product (IMP) that doesn’t already hold a Drug Identification Number (DIN) for the proposed indication and patient population.

Two mechanics define the process:

Under C.05.005(1), a sponsor must submit a CTA to Health Canada and wait 30 calendar days before authorizing any Canadian trial site to enroll its first subject. If Health Canada issues no Notice of Non-Compliance (NON-C) within that window, the sponsor receives a default authorization. There’s no formal approval letter. The silence is the green light.

Under C.05.005(4), if Health Canada does issue a NON-C, the 30-day clock stops completely. It doesn’t resume until the sponsor files a satisfactory response. In practice, that adds weeks to timelines that sponsors didn’t budget for — and that’s before any site startup activities at the Canadian institution.

For biologics and gene therapies, BGTD’s review is typically more intensive at Phase I, especially for novel mechanisms or first-in-human studies. Budget 45 to 60 days as a realistic planning estimate for those files, even without a NON-C. It’s not pessimism — it’s what the data from filed programs consistently shows.

What Goes Into a Canadian CTA Package

Canadian CTAs must follow the Common Technical Document (CTD) format — the same trilateral structure used for submissions to FDA, EMA, and PMDA. The content requirements, particularly in the quality module, have nuances that routinely catch sponsors off guard.

Administrative documentation

The package needs a cover letter explicitly stating the CTA type (initial, amendment, or notification), completed Form HC/SC 3011 (the Clinical Trial Site Information Form) for each Canadian site, the full clinical protocol with a synopsis, the current Investigator’s Brochure, and an Informed Consent Form template. Health Canada doesn’t formally approve the ICF but includes it in the file for reference during inspections.

Quality module (CTD Module 3 equivalent)

This is where most CTAs run into trouble. Health Canada expects a complete Module 3 quality package — not an abbreviated summary. For early-phase studies where manufacturing processes are still being optimized, sponsors sometimes submit a truncated quality section and receive an NON-C citing insufficient drug substance characterization data.

At minimum, the quality section needs drug substance and drug product specifications with analytical methods summaries, formulation rationale, stability data covering the proposed trial duration, and a GMP declaration for all IMP manufacturers.

The GMP declaration is frequently the piece that delays submissions. If the drug substance is manufactured at a non-Canadian facility that hasn’t been directly inspected by Health Canada, you’ll need to demonstrate compliance with Division 2 of Part C of the Food and Drug Regulations — Canada’s GMP requirements — through certification or equivalence documentation. Mutual Recognition Agreements (MRAs) simplify this for EU and certain other jurisdictions. For facilities without MRA coverage, it becomes a documentation exercise, and it takes time to assemble correctly.

Non-clinical and clinical modules

For Phase I first-in-human studies, the non-clinical package must satisfy ICH M3(R2) guidance on non-clinical safety studies. Health Canada explicitly references ICH guidance, and reviewers will cite gaps against ICH M3(R2) directly in any NON-C. For Phase II and III filings of compounds with existing human safety data, the non-clinical requirements are substantially reduced — but the Module 2.5 clinical overview must thoroughly characterize the emerging safety and efficacy profile, not just summarize the protocol.

The 30-Day Clock — And the Most Common Ways It Stops

Health Canada typically issues a Screening Letter within 5 to 7 business days of receipt when the submission is administratively complete. This letter confirms the 30-day clock has started. If a Screening Letter doesn’t arrive within that window, follow up with your reviewer — a submission that fails administrative screening restarts the clock, and Health Canada won’t always proactively notify the sponsor before the deadline matters.

The NON-C triggers we see most frequently in practice:

1. Incomplete CTD quality sections — particularly missing stability data or inadequate qualification of degradation impurities
2. GMP documentation gaps — especially for API manufacturers in jurisdictions without an MRA with Health Canada
3. Protocol inconsistencies — dose levels that don’t match the safety margins documented in the IB, or inclusion/exclusion criteria that don’t align with the non-clinical population studied
4. Missing or unsigned Form HC/SC 3011 — administratively simple, but a consistently common hold point
5. Statistics plan deficiencies — for Phase II/III studies, Health Canada’s biostatistics reviewers can hold a file on the primary endpoint analysis if the SAP lacks adequate power assumptions or multiplicity controls

A well-prepared NON-C response typically receives a Health Canada decision within 15 to 20 business days, but that’s not codified in regulation. The response quality matters enormously. Partial responses that address some but not all reviewer concerns extend timelines further — sometimes prompting a second NON-C on outstanding issues.

Post-Authorization Obligations Sponsors Frequently Underestimate

Getting the CTA authorized is the start, not the finish. Division 5 imposes several ongoing compliance obligations that sponsors running Canadian sites as secondary markets often miss until an inspection surfaces them.

Annual Safety Reports (ASRs): Under C.05.009, the sponsor must submit an ASR to Health Canada within 60 days of each anniversary of the CTA authorization date. The ASR must include a cumulative safety summary, the current Investigator’s Brochure, enrollment figures by site, and a summary of protocol amendments made during the year. Missing the 60-day window is a compliance deficiency — it surfaces in inspection findings and can complicate future submission reviews with the same directorate.

Expedited safety reporting: Under C.05.011, Suspected Unexpected Serious Adverse Reactions (SUSARs) must reach Health Canada within 15 calendar days of the sponsor becoming aware of the event. For fatal or life-threatening SUSARs, the initial report drops to 7 calendar days, with a complete follow-up within 15 days. These timelines run concurrently with FDA and EMA SUSAR reporting obligations, but Health Canada requires its own separate notification — a global safety report submitted only to FDA or EMA doesn’t satisfy the Canadian requirement.

Protocol amendments: Significant amendments — those affecting subject safety, the risk-benefit profile, or scientific validity — require a CTA amendment submission before implementation at Canadian sites. The same 30-day default clock applies to amendments. Sponsors running global trials frequently implement FDA-approved protocol amendments at Canadian sites before the Canadian amendment CTA is processed. That’s a compliance gap, and Health Canada’s compliance and enforcement team has cited it in sponsor inspection findings.

Trial completion notification: Under C.05.012, the sponsor must notify Health Canada within 90 days of completing or discontinuing a trial in Canada. This notification is consistently overlooked during closeout — but its absence is documented when Health Canada conducts periodic compliance reviews of trial programs.

Why Pre-Submission Planning Makes or Breaks Canadian CTA Timelines

The Division 5 process rewards sponsors who build the package correctly from the start. An 8- to 12-week pre-submission runway — used to review the quality package against current Health Canada expectations, resolve GMP documentation gaps, and map the protocol against the non-clinical dataset — is worth considerably more than expedited work on a NON-C response while your sites sit idle.

Our team at Androxa works with pharmaceutical sponsors, CROs, and CMOs at the pre-CTA stage: reviewing quality packages before submission, identifying documentation gaps before Health Canada does, and providing regulatory strategy support through the trial lifecycle in Canada. We’ve seen what generates NON-Cs and what doesn’t — and the patterns are consistent enough that most of them are preventable.

The 30-day default authorization timeline is genuinely achievable. But it requires a complete package on day one — not one rebuilt under time pressure after Health Canada has already stopped the clock.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Analytical Testing for IND and CTA Submissions: What Accredited Labs Provide — Qalitex Laboratories outlines how ISO 17025-accredited analytical data supports regulatory submissions for drug sponsors in North America
• EU Clinical Trial Regulation (CTR) and What It Means for Multi-Region Sponsors — Care Europe covers the EU’s CTR framework for sponsors managing parallel trial authorizations in both Canada and Europe